1
|
Santos BF, Grenho I, Martel PJ, Ferreira BI, Link W. Correction: FOXO family isoforms. Cell Death Dis 2023; 14:797. [PMID: 38057340 DOI: 10.1038/s41419-023-06328-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/08/2023]
Affiliation(s)
- Bruno F Santos
- Algarve Biomedical Center Research Institute-ABC-RI, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
- Faculty of Medicine and Biomedical Sciences, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
- Centro Hospitalar Universitário do Algarve (CHUA). Rua Leão Penedo, 8000-386, Faro, Portugal
| | - Inês Grenho
- Algarve Biomedical Center Research Institute-ABC-RI, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
- Faculty of Medicine and Biomedical Sciences, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
| | - Paulo J Martel
- Center for Health Technology and Services Research (CINTESIS)@RISE, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
| | - Bibiana I Ferreira
- Algarve Biomedical Center Research Institute-ABC-RI, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal.
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal.
- Faculty of Medicine and Biomedical Sciences, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal.
| | - Wolfgang Link
- Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM). Arturo Duperier 4, 28029, Madrid, Spain.
| |
Collapse
|
2
|
Santos BF, Grenho I, Martel PJ, Ferreira BI, Link W. FOXO family isoforms. Cell Death Dis 2023; 14:702. [PMID: 37891184 PMCID: PMC10611805 DOI: 10.1038/s41419-023-06177-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Revised: 06/30/2023] [Accepted: 09/26/2023] [Indexed: 10/29/2023]
Abstract
FOXO family of proteins are transcription factors involved in many physiological and pathological processes including cellular homeostasis, stem cell maintenance, cancer, metabolic, and cardiovascular diseases. Genetic evidence has been accumulating to suggest a prominent role of FOXOs in lifespan regulation in animal systems from hydra, C elegans, Drosophila, and mice. Together with the observation that FOXO3 is the second most replicated gene associated with extreme human longevity suggests that pharmacological targeting of FOXO proteins can be a promising approach to treat cancer and other age-related diseases and extend life and health span. However, due to the broad range of cellular functions of the FOXO family members FOXO1, 3, 4, and 6, isoform-specific targeting of FOXOs might lead to greater benefits and cause fewer side effects. Therefore, a deeper understanding of the common and specific features of these proteins as well as their redundant and specific functions in our cells represents the basis of specific targeting strategies. In this review, we provide an overview of the evolution, structure, function, and disease-relevance of each of the FOXO family members.
Collapse
Affiliation(s)
- Bruno F Santos
- Algarve Biomedical Center Research Institute-ABC-RI, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
- Faculty of Medicine and Biomedical Sciences, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
- Centro Hospitalar Universitário do Algarve (CHUA). Rua Leão Penedo, 8000-386, Faro, Portugal
| | - Inês Grenho
- Algarve Biomedical Center Research Institute-ABC-RI, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
- Faculty of Medicine and Biomedical Sciences, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
| | - Paulo J Martel
- Center for Health Technology and Services Research (CINTESIS)@RISE, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal
| | - Bibiana I Ferreira
- Algarve Biomedical Center Research Institute-ABC-RI, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal.
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal.
- Faculty of Medicine and Biomedical Sciences, University of Algarve, Campus de Gambelas, 8005-139, Faro, Portugal.
| | - Wolfgang Link
- Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM). Arturo Duperier 4, 28029, Madrid, Spain.
| |
Collapse
|
3
|
Malik N, Ferreira BI, Hollstein PE, Curtis SD, Trefts E, Novak SW, Yu J, Gilson R, Hellberg K, Fang L, Sheridan A, Hah N, Shadel GS, Manor U, Shaw RJ. Induction of lysosomal and mitochondrial biogenesis by AMPK phosphorylation of FNIP1. Science 2023; 380:eabj5559. [PMID: 37079666 PMCID: PMC10794112 DOI: 10.1126/science.abj5559] [Citation(s) in RCA: 32] [Impact Index Per Article: 32.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Accepted: 03/22/2023] [Indexed: 04/22/2023]
Abstract
Cells respond to mitochondrial poisons with rapid activation of the adenosine monophosphate-activated protein kinase (AMPK), causing acute metabolic changes through phosphorylation and prolonged adaptation of metabolism through transcriptional effects. Transcription factor EB (TFEB) is a major effector of AMPK that increases expression of lysosome genes in response to energetic stress, but how AMPK activates TFEB remains unresolved. We demonstrate that AMPK directly phosphorylates five conserved serine residues in folliculin-interacting protein 1 (FNIP1), suppressing the function of the folliculin (FLCN)-FNIP1 complex. FNIP1 phosphorylation is required for AMPK to induce nuclear translocation of TFEB and TFEB-dependent increases of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) and estrogen-related receptor alpha (ERRα) messenger RNAs. Thus, mitochondrial damage triggers AMPK-FNIP1-dependent nuclear translocation of TFEB, inducing sequential waves of lysosomal and mitochondrial biogenesis.
Collapse
Affiliation(s)
- Nazma Malik
- Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Bibiana I. Ferreira
- Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Pablo E. Hollstein
- Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Stephanie D. Curtis
- Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Elijah Trefts
- Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Sammy Weiser Novak
- Biophotonics Core, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Jingting Yu
- Bioinformatics Core, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Rebecca Gilson
- Biophotonics Core, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Kristina Hellberg
- Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Lingjing Fang
- Biophotonics Core, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Arlo Sheridan
- Biophotonics Core, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Nasun Hah
- Next Generation Sequencing Core, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Gerald S. Shadel
- Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Uri Manor
- Biophotonics Core, The Salk Institute for Biological Studies, La Jolla, CA, USA
| | - Reuben J. Shaw
- Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA
| |
Collapse
|
4
|
Kislaya I, Casaca P, Borges V, Sousa C, Ferreira BI, Fonte A, Fernandes E, Dias CM, Duarte S, Almeida JP, Grenho I, Coelho L, Ferreira R, Ferreira PP, Borges CM, Isidro J, Pinto M, Menezes L, Sobral D, Nunes A, Santos D, Gonçalves AM, Vieira L, Gomes JP, Leite PP, Nunes B, Machado A, Peralta-Santos A. Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal. Emerg Infect Dis 2023; 29:569-575. [PMID: 36737101 PMCID: PMC9973705 DOI: 10.3201/eid2903.221367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
We estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April-June 2022, we implemented a case-case and cohort study and classified lineages using whole-genome sequencing or spike gene target failure. For the case-case study, we estimated the adjusted odds ratios (aORs) of vaccination using a logistic regression. For the cohort study, we estimated VE against disease progression using a penalized logistic regression. We observed no reduced VE for primary (aOR 1.07 [95% CI 0.93-1.23]) or booster (aOR 0.96 [95% CI 0.84-1.09]) vaccination against BA.5 infection. Among BA.5 case-patients, booster VE against progression to hospitalization was lower than that among BA.2 case-patients (VE 77% [95% CI 49%-90%] vs. VE 93% [95% CI 86%-97%]). Although booster vaccination is less effective against BA.5 than against BA.2, it offers substantial protection against progression from BA.5 infection to severe disease.
Collapse
Affiliation(s)
| | | | - Vítor Borges
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Carlos Sousa
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Bibiana I. Ferreira
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Ana Fonte
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Eugénia Fernandes
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Carlos Matias Dias
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Sílvia Duarte
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - José Pedro Almeida
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Inês Grenho
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Luís Coelho
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Rita Ferreira
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Patrícia Pita Ferreira
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Cláudia Medeiros Borges
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Joana Isidro
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Miguel Pinto
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Luís Menezes
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Daniel Sobral
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Alexandra Nunes
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Daniela Santos
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - António Maia Gonçalves
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Luís Vieira
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - João Paulo Gomes
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Pedro Pinto Leite
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | - Baltazar Nunes
- Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal (I. Kislaya, V. Borges, C. Matias Dias, S. Duarte, L. Coelho, R. Ferreira, J. Isidro, M. Pinto, D. Sobral, A. Nunes, D. Santos, L. Vieira, J.P. Gomes, B. Nunes, A. Machado)
- Comprehensive Health Research Centre, Lisbon (I. Kislaya, C. Matias Dias, B. Nunes, A. Machado, A. Peralta-Santos)
- Direção-Geral da Saúde, Lisbon (P. Casaca, E. Fernandes, P. Pita Ferreira, P. Pinto Leite, A. Peralta-Santos)
- Unilabs, Porto, Portugal (C. Sousa, J.P. Almeida, L. Menezes, A. Maia Gonçalves)
- Algarve Biomedical Center Research Institute, Faro, Portugal (B.I. Ferreira, I. Grenho)
- Administração Central do Sistema de Saúde, Lisbon (A. Fonte, C.M. Borges)
| | | | | |
Collapse
|
5
|
Jimenez L, Mayoral-Varo V, Amenábar C, Ortega J, Sequeira JGN, Machuqueiro M, Mourato C, Silvestri R, Angeli A, Carta F, Supuran CT, Megías D, Ferreira BI, Link W. Multiplexed cellular profiling identifies an organoselenium compound as an inhibitor of CRM1-mediated nuclear export. Traffic 2022; 23:587-599. [PMID: 36353954 PMCID: PMC10099545 DOI: 10.1111/tra.12872] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Revised: 10/31/2022] [Accepted: 11/03/2022] [Indexed: 11/11/2022]
Abstract
Chromosomal region maintenance 1 (CRM1 also known as Xpo1 and exportin-1) is the receptor for the nuclear export controlling the intracellular localization and function of many cellular and viral proteins that play a crucial role in viral infections and cancer. The inhibition of CRM1 has emerged as a promising therapeutic approach to interfere with the lifecycle of many viruses, for the treatment of cancer, and to overcome therapy resistance. Recently, selinexor has been approved as the first CRM1 inhibitor for the treatment of multiple myeloma, providing proof of concept for this therapeutic option with a new mode of action. However, selinexor is associated with dose-limiting toxicity and hence, the discovery of alternative small molecule leads that could be developed as less toxic anticancer and antiviral therapeutics will have a significant impact in the clinic. Here, we report a CRM1 inhibitor discovery platform. The development of this platform includes reporter cell lines that monitor CRM1 activity by using red fluorescent protein or green fluorescent protein-labeled HIV-1 Rev protein with a strong heterologous nuclear export signal. Simultaneously, the intracellular localization of other proteins, to be interrogated for their capacity to undergo CRM1-mediated export, can be followed by co-culturing stable cell lines expressing fluorescent fusion proteins. We used this platform to interrogate the mode of nuclear export of several proteins, including PDK1, p110α, STAT5A, FOXO1, 3, 4 and TRIB2, and to screen a compound collection. We show that while p110α partially relies on CRM1-dependent nuclear export, TRIB2 is exported from the nucleus in a CRM1-independent manner. Compound screening revealed the striking activity of an organoselenium compound on the CRM1 nuclear export receptor.
Collapse
Affiliation(s)
- Lucia Jimenez
- Cancer Biology Department, Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain
| | - Victor Mayoral-Varo
- Cancer Biology Department, Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain
| | - Carlos Amenábar
- Cancer Biology Department, Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain.,Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - Judit Ortega
- Cancer Biology Department, Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain
| | - João G N Sequeira
- BioISI--Instituto de Biosistemas e Ciências Integrativas, Faculdade de Ciências, Universidade de Lisboa, Lisbon, Portugal
| | - Miguel Machuqueiro
- BioISI--Instituto de Biosistemas e Ciências Integrativas, Faculdade de Ciências, Universidade de Lisboa, Lisbon, Portugal
| | - Cristiana Mourato
- ABC-RI, Algarve Biomedical Center Research Institute, Algarve Biomedical Center, Faro, Portugal.,Faculty of Medicine and Biomedical Sciences, University of Algarve, Faro, Portugal
| | - Romano Silvestri
- Laboratory Affiliated with the Institute Pasteur Italy-Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy
| | - Andrea Angeli
- Università degli Studi di Firenze, NEUROFARBA Dept., Sezione di Farmaceutica e Nutraceutica, Florence, Italy
| | - Fabrizio Carta
- Università degli Studi di Firenze, NEUROFARBA Dept., Sezione di Farmaceutica e Nutraceutica, Florence, Italy
| | - Claudiu T Supuran
- Università degli Studi di Firenze, NEUROFARBA Dept., Sezione di Farmaceutica e Nutraceutica, Florence, Italy
| | - Diego Megías
- Advanced Optical Microscopy Unit, Instituto de salud Carlos III, Madrid, Spain
| | - Bibiana I Ferreira
- ABC-RI, Algarve Biomedical Center Research Institute, Algarve Biomedical Center, Faro, Portugal.,Faculty of Medicine and Biomedical Sciences, University of Algarve, Faro, Portugal
| | - Wolfgang Link
- Cancer Biology Department, Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain
| |
Collapse
|
6
|
Jimenez L, Amenabar C, Mayoral-Varo V, Mackenzie TA, Ramos MC, Silva A, Calissi G, Grenho I, Blanco-Aparicio C, Pastor J, Megías D, Ferreira BI, Link W. mTORC2 Is the Major Second Layer Kinase Negatively Regulating FOXO3 Activity. Molecules 2022; 27:molecules27175414. [PMID: 36080182 PMCID: PMC9457944 DOI: 10.3390/molecules27175414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Revised: 08/10/2022] [Accepted: 08/22/2022] [Indexed: 11/16/2022] Open
Abstract
Forkhead box O (FOXO) proteins are transcription factors involved in cancer and aging and their pharmacological manipulation could be beneficial for the treatment of cancer and healthy aging. FOXO proteins are mainly regulated by post-translational modifications including phosphorylation, acetylation and ubiquitination. As these modifications are reversible, activation and inactivation of FOXO factors is attainable through pharmacological treatment. One major regulatory input of FOXO signaling is mediated by protein kinases. Here, we use specific inhibitors against different kinases including PI3K, mTOR, MEK and ALK, and other receptor tyrosine kinases (RTKs) to determine their effect on FOXO3 activity. While we show that inhibition of PI3K efficiently drives FOXO3 into the cell nucleus, the dual PI3K/mTOR inhibitors dactolisib and PI-103 induce nuclear FOXO translocation more potently than the PI3Kδ inhibitor idelalisib. Furthermore, specific inhibition of mTOR kinase activity affecting both mTORC1 and mTORC2 potently induced nuclear translocation of FOXO3, while rapamycin, which specifically inhibits the mTORC1, failed to affect FOXO3. Interestingly, inhibition of the MAPK pathway had no effect on the localization of FOXO3 and upstream RTK inhibition only weakly induced nuclear FOXO3. We also measured the effect of the test compounds on the phosphorylation status of AKT, FOXO3 and ERK, on FOXO-dependent transcriptional activity and on the subcellular localization of other FOXO isoforms. We conclude that mTORC2 is the most important second layer kinase negatively regulating FOXO activity.
Collapse
Affiliation(s)
- Lucia Jimenez
- Institute of Biomedical Research Alberto Sols (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
| | - Carlos Amenabar
- Institute of Biomedical Research Alberto Sols (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
| | - Victor Mayoral-Varo
- Institute of Biomedical Research Alberto Sols (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
| | - Thomas A. Mackenzie
- Fundación MEDINA, Health Sciences Technology Park, Avda. del Conocimiento 34, 18016 Granada, Spain
| | - Maria C. Ramos
- Fundación MEDINA, Health Sciences Technology Park, Avda. del Conocimiento 34, 18016 Granada, Spain
| | - Andreia Silva
- ABC-RI, Algarve Biomedical Center Research Institute, Algarve Biomedical Center, 8005-139 Faro, Portugal
- Faculty of Medicine and Biomedical Sciences, University of Algarve, 8005-139 Faro, Portugal
| | - Giampaolo Calissi
- Institute of Biomedical Research Alberto Sols (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
| | - Inês Grenho
- ABC-RI, Algarve Biomedical Center Research Institute, Algarve Biomedical Center, 8005-139 Faro, Portugal
- Faculty of Medicine and Biomedical Sciences, University of Algarve, 8005-139 Faro, Portugal
| | - Carmen Blanco-Aparicio
- Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
| | - Joaquin Pastor
- Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
| | - Diego Megías
- Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
| | - Bibiana I. Ferreira
- ABC-RI, Algarve Biomedical Center Research Institute, Algarve Biomedical Center, 8005-139 Faro, Portugal
- Faculty of Medicine and Biomedical Sciences, University of Algarve, 8005-139 Faro, Portugal
- Correspondence: (B.I.F.); (W.L.)
| | - Wolfgang Link
- Institute of Biomedical Research Alberto Sols (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
- Correspondence: (B.I.F.); (W.L.)
| |
Collapse
|
7
|
Jimenez L, Silva A, Calissi G, Grenho I, Monteiro R, Mayoral-Varo V, Blanco-Aparicio C, Pastor J, Bustos V, Bracher F, Megías D, Ferreira BI, Link W. Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3. J Gerontol A Biol Sci Med Sci 2022; 77:1485-1493. [PMID: 34508571 PMCID: PMC9373959 DOI: 10.1093/gerona/glab265] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Indexed: 12/01/2022] Open
Abstract
Several chemical compounds including natural products have been suggested as being effective against age-related diseases or as beneficial for a healthy life. On the other hand, forkhead box O (FOXO) proteins are emerging as key cellular components associated with extreme human longevity. FOXO proteins are mainly regulated by posttranslational modifications and as these modifications are reversible, activation and inactivation of FOXO are attainable through pharmacological treatment. Here, we questioned whether a panel of compounds with known health-beneficial properties has the capacity to induce the activity of FOXO factors. We show that resveratrol, a phytoalexin present in grapes and other food products, the amide alkaloid piperlongumine found in the fruit of the long pepper, and the plant-derived β-carboline compound harmine induced nuclear translocation of FOXO3. We also show that piperlongumine and harmine but not resveratrol activate FOXO-dependent transcription. We determined the half maximal effective concentration (EC50) values for resveratrol, piperlongumine, and harmine for FOXO translocation, and analyzed their inhibitory impact on chromosomal maintenance 1 (CRM1)-mediated nuclear export and the production of reactive oxygen species (ROS). We also used chemical biology approach and Western blot analysis to explore the underlying molecular mechanisms. We show that harmine, piperlongumine, and resveratrol activate FOXO3 independently of phosphoinositide 3-kinase (PI3K)/AKT signaling and the CRM1-mediated nuclear export. The effect of harmine on FOXO3 activity is at least partially mediated through the inhibition of dual-specificity tyrosine (Y) phosphorylationregulated kinase 1A (DYRK1A) and can be reverted by the inhibition of sirtuins (SIRTs).
Collapse
Affiliation(s)
- Lucia Jimenez
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| | - Andreia Silva
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal
- Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Campus de Gambelas, Faro, Portugal
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, Portugal
| | - Giampaolo Calissi
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| | - Inês Grenho
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal
- Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Campus de Gambelas, Faro, Portugal
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, Portugal
| | - Rita Monteiro
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal
- Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Campus de Gambelas, Faro, Portugal
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, Portugal
| | - Victor Mayoral-Varo
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| | | | - Joaquin Pastor
- Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | | | - Franz Bracher
- Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians University, Munich, Germany
| | - Diego Megías
- Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Bibiana I Ferreira
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Faro, Portugal
- Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Campus de Gambelas, Faro, Portugal
- Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, Portugal
| | - Wolfgang Link
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| |
Collapse
|
8
|
De Sousa-Coelho AL, Aureliano M, Fraqueza G, Serrão G, Gonçalves J, Sánchez-Lombardo I, Link W, Ferreira BI. Decavanadate and metformin-decavanadate effects in human melanoma cells. J Inorg Biochem 2022; 235:111915. [PMID: 35834898 DOI: 10.1016/j.jinorgbio.2022.111915] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 06/21/2022] [Accepted: 07/03/2022] [Indexed: 10/17/2022]
Abstract
Decavanadate is a polyoxometalate (POMs) that has shown extensive biological activities, including antidiabetic and anticancer activity. Importantly, vanadium-based compounds as well as antidiabetic biguanide drugs, such as metformin, have shown to exert therapeutic effects in melanoma. A combination of these agents, the metformin-decavanadate complex, was also recognized for its antidiabetic effects and recently described as a better treatment than the monotherapy with metformin enabling lower dosage in rodent models of diabetes. Herein, we compare the effects of decavanadate and metformin-decavanadate on Ca2+-ATPase activity in sarcoplasmic reticulum vesicles from rabbit skeletal muscles and on cell signaling events and viability in human melanoma cells. We show that unlike the decavanadate-mediated non-competitive mechanism, metformin-decavanadate inhibits Ca2+-ATPase by a mixed-type competitive-non-competitive inhibition with an IC50 value about 6 times higher (87 μM) than the previously described for decavanadate (15 μM). We also found that both decavanadate and metformin-decavanadate exert antiproliferative effects on melanoma cells at 10 times lower concentrations than monomeric vanadate. Western blot analysis revealed that both, decavanadate and metformin-decavanadate increased phosphorylation of extracellular signal-regulated kinase (ERK) and serine/threonine protein kinase AKT signaling proteins upon 24 h drug exposure, suggesting that the anti-proliferative activities of these compounds act independent of growth-factor signaling pathways.
Collapse
Affiliation(s)
- Ana Luísa De Sousa-Coelho
- Algarve Biomedical Center Research Institute (ABC-RI), Universidade do Algarve, Faro, Portugal; Algarve Biomedical Center (ABC), Faro, Portugal; Escola Superior de Saúde (ESS), Universidade do Algarve, Faro, Portugal.
| | - Manuel Aureliano
- Faculdade de Ciências e Tecnologia (FCT), Universidade do Algarve, Faro, Portugal; Centro de Ciências do Mar (CCMar), Universidade do Algarve, Faro, Portugal.
| | - Gil Fraqueza
- Centro de Ciências do Mar (CCMar), Universidade do Algarve, Faro, Portugal; Instituto Superior de Engenharia (ISE), Universidade do Algarve, Faro, Portugal
| | - Gisela Serrão
- Algarve Biomedical Center Research Institute (ABC-RI), Universidade do Algarve, Faro, Portugal
| | - João Gonçalves
- Faculdade de Medicina e Ciências Biomédicas, Universidade do Algarve, Faro, Portugal
| | - Irma Sánchez-Lombardo
- División Académica de Ciencias Básicas, Universidad Juárez Autónoma de Tabasco, Cunduacán, Mexico
| | - Wolfgang Link
- Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM). Madrid, Spain
| | - Bibiana I Ferreira
- Algarve Biomedical Center Research Institute (ABC-RI), Universidade do Algarve, Faro, Portugal; Algarve Biomedical Center (ABC), Faro, Portugal; Faculdade de Medicina e Ciências Biomédicas, Universidade do Algarve, Faro, Portugal
| |
Collapse
|
9
|
Fernandes MT, Yassuda V, Bragança J, Link W, Ferreira BI, De Sousa-Coelho AL. Tribbles Gene Expression Profiles in Colorectal Cancer. GastrointestDisord 2021; 3:218-236. [DOI: https:/doi.org/10.3390/gidisord3040021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 09/01/2023] Open
Abstract
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of death due to cancer in the world. Therefore, the identification of novel druggable targets is urgently needed. Tribbles proteins belong to a pseudokinase family, previously recognized in CRC as oncogenes and potential therapeutic targets. Here, we analyzed the expression of TRIB1, TRIB2, and TRIB3 simultaneously in 33 data sets from CRC based on available GEO profiles. We show that all three Tribbles genes are overrepresented in CRC cell lines and primary tumors, though depending on specific features of the CRC samples. Higher expression of TRIB2 in the tumor microenvironment and TRIB3 overexpression in an early stage of CRC development, unveil a potential and unexplored role for these proteins in the context of CRC. Differential Tribbles expression was also explored in diverse cellular experimental conditions where either genetic or pharmacological approaches were used, providing novel hints for future research. This comprehensive bioinformatic analysis provides new insights into Tribbles gene expression and transcript regulation in CRC.
Collapse
|
10
|
Ferreira BI, Santos B, Link W, De Sousa-Coelho AL. Tribbles Pseudokinases in Colorectal Cancer. Cancers (Basel) 2021; 13:cancers13112825. [PMID: 34198908 PMCID: PMC8201230 DOI: 10.3390/cancers13112825] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2021] [Revised: 05/29/2021] [Accepted: 05/31/2021] [Indexed: 12/18/2022] Open
Abstract
The Tribbles family of pseudokinases controls a wide number of processes during cancer on-set and progression. However, the exact contribution of each of the three family members is still to be defined. Their function appears to be context-dependent as they can act as oncogenes or tumor suppressor genes. They act as scaffolds modulating the activity of several signaling pathways involved in different cellular processes. In this review, we discuss the state-of-knowledge for TRIB1, TRIB2 and TRIB3 in the development and progression of colorectal cancer. We take a perspective look at the role of Tribbles proteins as potential biomarkers and therapeutic targets. Specifically, we chronologically systematized all available articles since 2003 until 2020, for which Tribbles were associated with colorectal cancer human samples or cell lines. Herein, we discuss: (1) Tribbles amplification and overexpression; (2) the clinical significance of Tribbles overexpression; (3) upstream Tribbles gene and protein expression regulation; (4) Tribbles pharmacological modulation; (5) genetic modulation of Tribbles; and (6) downstream mechanisms regulated by Tribbles; establishing a comprehensive timeline, essential to better consolidate the current knowledge of Tribbles' role in colorectal cancer.
Collapse
Affiliation(s)
- Bibiana I. Ferreira
- Centre for Biomedical Research (CBMR), Campus of Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal; (B.I.F.); (B.S.)
- Algarve Biomedical Center (ABC), Campus de Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal
- Faculdade de Medicina e Ciências Biomédicas (FMCB), Campus de Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal
| | - Bruno Santos
- Centre for Biomedical Research (CBMR), Campus of Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal; (B.I.F.); (B.S.)
- Algarve Biomedical Center (ABC), Campus de Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal
- Serviço de Anatomia Patológica, Centro Hospital Universitário do Algarve (CHUA), 8000-386 Faro, Portugal
| | - Wolfgang Link
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
- Correspondence: (W.L.); (A.L.D.S.-C.)
| | - Ana Luísa De Sousa-Coelho
- Centre for Biomedical Research (CBMR), Campus of Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal; (B.I.F.); (B.S.)
- Algarve Biomedical Center (ABC), Campus de Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal
- Escola Superior de Saúde (ESS), Campus de Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal
- Correspondence: (W.L.); (A.L.D.S.-C.)
| |
Collapse
|
11
|
Machado S, Silva A, De Sousa-Coelho AL, Duarte I, Grenho I, Santos B, Mayoral-Varo V, Megias D, Sánchez-Cabo F, Dopazo A, Ferreira BI, Link W. Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance. Cancers (Basel) 2020; 12:cancers12123689. [PMID: 33316942 PMCID: PMC7763856 DOI: 10.3390/cancers12123689] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Accepted: 12/02/2020] [Indexed: 02/07/2023] Open
Abstract
Simple Summary Poor survival and treatment failure of patients with cancer are mainly due to resistance to therapy. Tribbles homologue 2 (TRIB2) has recently been identified as a protein that promotes resistance to several anti-cancer drugs. In this study, RNA sequencing and bioinformatics analysis were used with the aim of characterizing the impact of TRIB2 on the expression of genes and developing pharmacological strategies to revert these TRIB2-mediated changes, thereby overcoming therapy resistance. We show that two naturally occurring alkaloids, harmine and piperlongumine, inverse the gene expression profile produced by TRIB2 and sensitize cancer cells to anti-cancer drugs. Our data suggest that harmine and piperlongumine or similar compounds might have the potential to overcome TRIB2-mediated therapy resistance in cancer patients. Abstract Therapy resistance is responsible for most relapses in patients with cancer and is the major challenge to improving the clinical outcome. The pseudokinase Tribbles homologue 2 (TRIB2) has been characterized as an important driver of resistance to several anti-cancer drugs, including the dual ATP-competitive PI3K and mTOR inhibitor dactolisib (BEZ235). TRIB2 promotes AKT activity, leading to the inactivation of FOXO transcription factors, which are known to mediate the cell response to antitumor drugs. To characterize the downstream events of TRIB2 activity, we analyzed the gene expression profiles of isogenic cell lines with different TRIB2 statuses by RNA sequencing. Using a connectivity map-based computational approach, we identified drug-induced gene-expression profiles that invert the TRIB2-associated expression profile. In particular, the natural alkaloids harmine and piperlongumine not only produced inverse gene expression profiles but also synergistically increased BEZ235-induced cell toxicity. Importantly, both agents promote FOXO nuclear translocation without interfering with the nuclear export machinery and induce the transcription of FOXO target genes. Our results highlight the great potential of this approach for drug repurposing and suggest that harmine and piperlongumine or similar compounds might be useful in the clinic to overcome TRIB2-mediated therapy resistance in cancer patients.
Collapse
Affiliation(s)
- Susana Machado
- Centre for Biomedical Research (CBMR), Universidade do Algarve, Campus of Gambelas, Building 8, Room 1.12, 8005-139 Faro, Portugal; (S.M.); (A.S.); (A.L.D.S.-C.); (I.D.); (I.G.); (B.S.)
- Algarve Biomedical Center (ABC), Universidade do Algarve, Campus de Gambelas, 8005-139 Faro, Portugal
| | - Andreia Silva
- Centre for Biomedical Research (CBMR), Universidade do Algarve, Campus of Gambelas, Building 8, Room 1.12, 8005-139 Faro, Portugal; (S.M.); (A.S.); (A.L.D.S.-C.); (I.D.); (I.G.); (B.S.)
- Algarve Biomedical Center (ABC), Universidade do Algarve, Campus de Gambelas, 8005-139 Faro, Portugal
| | - Ana Luísa De Sousa-Coelho
- Centre for Biomedical Research (CBMR), Universidade do Algarve, Campus of Gambelas, Building 8, Room 1.12, 8005-139 Faro, Portugal; (S.M.); (A.S.); (A.L.D.S.-C.); (I.D.); (I.G.); (B.S.)
- Algarve Biomedical Center (ABC), Universidade do Algarve, Campus de Gambelas, 8005-139 Faro, Portugal
| | - Isabel Duarte
- Centre for Biomedical Research (CBMR), Universidade do Algarve, Campus of Gambelas, Building 8, Room 1.12, 8005-139 Faro, Portugal; (S.M.); (A.S.); (A.L.D.S.-C.); (I.D.); (I.G.); (B.S.)
- Algarve Biomedical Center (ABC), Universidade do Algarve, Campus de Gambelas, 8005-139 Faro, Portugal
| | - Inês Grenho
- Centre for Biomedical Research (CBMR), Universidade do Algarve, Campus of Gambelas, Building 8, Room 1.12, 8005-139 Faro, Portugal; (S.M.); (A.S.); (A.L.D.S.-C.); (I.D.); (I.G.); (B.S.)
- Algarve Biomedical Center (ABC), Universidade do Algarve, Campus de Gambelas, 8005-139 Faro, Portugal
| | - Bruno Santos
- Centre for Biomedical Research (CBMR), Universidade do Algarve, Campus of Gambelas, Building 8, Room 1.12, 8005-139 Faro, Portugal; (S.M.); (A.S.); (A.L.D.S.-C.); (I.D.); (I.G.); (B.S.)
- Algarve Biomedical Center (ABC), Universidade do Algarve, Campus de Gambelas, 8005-139 Faro, Portugal
| | - Victor Mayoral-Varo
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain;
| | - Diego Megias
- Confocal Microscopy Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain;
| | - Fátima Sánchez-Cabo
- Vascular Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (F.S.-C.); (A.D.)
| | - Ana Dopazo
- Vascular Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain; (F.S.-C.); (A.D.)
| | - Bibiana I. Ferreira
- Centre for Biomedical Research (CBMR), Universidade do Algarve, Campus of Gambelas, Building 8, Room 1.12, 8005-139 Faro, Portugal; (S.M.); (A.S.); (A.L.D.S.-C.); (I.D.); (I.G.); (B.S.)
- Algarve Biomedical Center (ABC), Universidade do Algarve, Campus de Gambelas, 8005-139 Faro, Portugal
- Regenerative Medicine Program, Department of Biomedical Sciences and Medicine, Universidade do Algarve, Campus de Gambelas, 8005-139 Faro, Portugal
- Correspondence: (B.I.F.); (W.L.)
| | - Wolfgang Link
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain;
- Correspondence: (B.I.F.); (W.L.)
| |
Collapse
|
12
|
Abstract
The transport through the nuclear pore complex is used by cancer cells to evade tumor-suppressive mechanisms. Several tumor-suppressors have been shown to be excluded from the cell nucleus in cancer cells by the nuclear export receptor CRM1 and abnormal expression of CRM1 is oncogenic. Inhibition of CRM1 has long been postulated as potential approach for the treatment of cancer and to overcome therapy resistance. Furthermore, the nuclear export of viral components mediated by the CRM1 is crucial in various stages of the viral lifecycle and assembly of many viruses from diverse families, including coronavirus. However, the first nuclear export inhibitors failed or never entered into clinical trials. More recently CRM1 reemerged as a cancer target and a successful proof of concept was achieved with the clinical approval of Selinexor. The chemical complexity of natural products is a promising perspective for the discovery of new nuclear export inhibitors with a favorable toxicity profile. Several screening campaigns have been performed and several natural product-based nuclear export inhibitors have been identified. With this review we give an overview over the role of CRM1-mediated nuclear export in cancer and the effort made to identify and develop nuclear export inhibitors in particular from natural sources.
Collapse
Affiliation(s)
- Bibiana I Ferreira
- Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal.,Regenerative Medicine Program, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.,Algarve Biomedical Center (ABC), University of Algarve, Faro, Portugal
| | - Bastien Cautain
- Fundacion MEDINA Parque tecnológico ciencias de la salud, Granada, Spain.,Evotec France, Toulouse, France
| | - Inês Grenho
- Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal.,Regenerative Medicine Program, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.,Algarve Biomedical Center (ABC), University of Algarve, Faro, Portugal
| | - Wolfgang Link
- Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain
| |
Collapse
|
13
|
Jacinto FV, Link W, Ferreira BI. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine. J Cell Mol Med 2020; 24:3766-3778. [PMID: 32096600 PMCID: PMC7171402 DOI: 10.1111/jcmm.14916] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Revised: 10/23/2019] [Accepted: 11/13/2019] [Indexed: 12/26/2022] Open
Abstract
The recent development of the CRISPR/Cas9 system as an efficient and accessible programmable genome‐editing tool has revolutionized basic science research. CRISPR/Cas9 system‐based technologies have armed researchers with new powerful tools to unveil the impact of genetics on disease development by enabling the creation of precise cellular and animal models of human diseases. The therapeutic potential of these technologies is tremendous, particularly in gene therapy, in which a patient‐specific mutation is genetically corrected in order to treat human diseases that are untreatable with conventional therapies. However, the translation of CRISPR/Cas9 into the clinics will be challenging, since we still need to improve the efficiency, specificity and delivery of this technology. In this review, we focus on several in vitro, in vivo and ex vivo applications of the CRISPR/Cas9 system in human disease‐focused research, explore the potential of this technology in translational medicine and discuss some of the major challenges for its future use in patients.
Collapse
Affiliation(s)
- Filipe V Jacinto
- Centre for Biomedical Research (CBMR), Faro, Portugal.,Departamento de Medicina e Ciências Biomedicas (DCBM), Universidade do Algarve, Faro, Portugal.,Algarve Biomedical Center (ABC), Faro, Portugal
| | - Wolfgang Link
- Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain
| | - Bibiana I Ferreira
- Centre for Biomedical Research (CBMR), Faro, Portugal.,Departamento de Medicina e Ciências Biomedicas (DCBM), Universidade do Algarve, Faro, Portugal.,Algarve Biomedical Center (ABC), Faro, Portugal
| |
Collapse
|
14
|
Henriques V, Martins T, Link W, Ferreira BI. The Emerging Therapeutic Landscape of Advanced Melanoma. Curr Pharm Des 2019; 24:549-558. [PMID: 29366407 DOI: 10.2174/1381612824666180125093357] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Revised: 01/08/2018] [Accepted: 01/18/2018] [Indexed: 11/22/2022]
Abstract
Melanoma is the deadliest form of skin cancer being responsible for 80% of skin cancer deaths. Furthermore, the incidence of metastatic melanoma has increased over the past three decades with a mortality rate that continues to rise faster than most of all other cancers. The last few years have witnessed an unparalleled change in treatment options for patients with metastatic melanoma by the development of new therapeutic strategies like targeted therapies and immunotherapies that highly improved the patient's prognosis. Despite the paradigm- shifting success of these novel treatments, their effectiveness is still limited by intrinsic or acquired resistance. The objective of this review is to provide an overview of the new available treatment modalities, criteria to select patients who might benefit from a specific therapy, mechanisms of innate and acquired resistance to these treatments and to discuss strategies to overcome drug resistance.
Collapse
Affiliation(s)
- Vanessa Henriques
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Building 8, room 1.12, 8005-139 Faro, Portugal
| | - Teresa Martins
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Building 8, room 1.12, 8005-139 Faro, Portugal.,Department of Biomedical Sciences and Medicine, University of Algarve, 8005-139, Faro, Portugal.,Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, 8005-139 Faro, Portugal
| | - Wolfgang Link
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Building 8, room 1.12, 8005-139 Faro, Portugal.,Department of Biomedical Sciences and Medicine, University of Algarve, 8005-139, Faro, Portugal.,Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, 8005-139 Faro, Portugal
| | - Bibiana I Ferreira
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Building 8, room 1.12, 8005-139 Faro, Portugal.,Department of Biomedical Sciences and Medicine, University of Algarve, 8005-139, Faro, Portugal.,Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, 8005-139 Faro, Portugal
| |
Collapse
|
15
|
Henriques V, Machado S, Link W, Ferreira BI. Monitoring the Transcriptional Activity of FOXO Transcription Factors by Analyzing their Target Genes. Methods Mol Biol 2019; 1890:103-113. [PMID: 30414148 DOI: 10.1007/978-1-4939-8900-3_9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
Abstract
FOXO proteins represent a subfamily of transcription factors that belong to the forkhead family. The study of FOXO target genes can be performed using Real-Time PCR (RT-PCR). The RT-PCR is a sensitive method that allows the detection and quantification of minute amounts of nucleic acids. In RT-PCR the accumulation of the amplicon is detected and measured as the reaction progresses. Here, we describe the application of RT-PCR technique to monitor the transcriptional activity of FOXO transcription factors.
Collapse
Affiliation(s)
- Vanessa Henriques
- Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal
| | - Susana Machado
- Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal
| | - Wolfgang Link
- Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), Madrid, Spain
| | - Bibiana I Ferreira
- Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal. .,Regenerative Medicine Program, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal. .,Algarve Biomedical Center (ABC), University of Algarve, Faro, Portugal.
| |
Collapse
|
16
|
Abstract
Forkhead box O (FOXO) factors are tumor suppressor proteins commonly inactivated in human tumors. Furthermore, genetic variation within the FOXO3a gene is consistently associated with human longevity. FOXO proteins are usually inactivated by posttranslational modifications leading to cytoplasmic mislocalization. Therefore, the pharmacological activation by promoting nuclear localization of FOXOs is considered an attractive therapeutic approach to treat cancer and age-related diseases. We developed a cell-based imaging assay to screen for chemical agents capable of inhibiting the nuclear export and in turn trapping proteins that contain a nuclear export sequence including FOXO factors in the nucleus. The fluorescent signal of untreated assay cells localizes predominantly to the cytoplasm. Upon treatment with the nuclear export inhibitors the fluorescent-tagged reporter proteins appear as speckles in the nucleus. In a personalized medicine context, drugs capable of reactivating FOXO factors might be of enormous clinical value in human tumors in which these proteins are inactivated. Here, we describe the procedures for monitoring nuclear export which is suitable for high-throughput screening of compound collections.
Collapse
Affiliation(s)
- Susana Machado
- Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal
| | - Catarina Raposo
- Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal
| | - Bibiana I Ferreira
- Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal.,Regenerative Medicine Program, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal
| | - Wolfgang Link
- Instituto de Investigaciones BiomeÇdicas "Alberto Sols" (CSIC-UAM), Arturo Duperier, Madrid, Spain.
| |
Collapse
|
17
|
Ferreira BI, Lie MK, Engelsen AST, Machado S, Link W, Lorens JB. Adaptive mechanisms of resistance to anti-neoplastic agents. Medchemcomm 2017; 8:53-66. [PMID: 30108690 PMCID: PMC6072477 DOI: 10.1039/c6md00394j] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/15/2016] [Accepted: 10/19/2016] [Indexed: 12/18/2022]
Abstract
Intrinsic and acquired resistance to conventional and targeted therapeutics is a fundamental reason for treatment failure in many cancer patients. Targeted approaches to overcome chemoresistance as well as resistance to targeted approaches require in depth understanding of the underlying molecular mechanisms. The anti-cancer activity of a drug can be limited by a broad variety of molecular events at different levels of drug action in a cell-autonomous and non-cell-autonomous manner. This review summarizes recent insights into the adaptive mechanisms used by tumours to resist therapy including cellular phenotypic plasticity, dynamic alterations of the tumour microenvironment, activation of redundant signal transduction pathways, modulation of drug target expression levels, and exploitation of pro-survival responses.
Collapse
Affiliation(s)
- Bibiana I Ferreira
- Centre for Biomedical Research (CBMR) , University of Algarve , Campus of Gambelas, Building 8, room 2.22 , 8005-139 Faro , Portugal
- Regenerative Medicine Program , Department of Biomedical Sciences and Medicine , University of Algarve , Campus de Gambelas , 8005-139 Faro , Portugal .
| | - Maria K Lie
- Department of Biomedicine , Centre for Cancer Biomarkers , University of Bergen , Jonas Lies Vei 91 , 5009 Bergen , Norway
- Department of Pathology , Haukeland University Hospital , Jonas Lies vei 65 , 5021 Bergen , Norway
| | - Agnete S T Engelsen
- Department of Biomedicine , Centre for Cancer Biomarkers , University of Bergen , Jonas Lies Vei 91 , 5009 Bergen , Norway
| | - Susana Machado
- Centre for Biomedical Research (CBMR) , University of Algarve , Campus of Gambelas, Building 8, room 2.22 , 8005-139 Faro , Portugal
- Regenerative Medicine Program , Department of Biomedical Sciences and Medicine , University of Algarve , Campus de Gambelas , 8005-139 Faro , Portugal .
| | - Wolfgang Link
- Centre for Biomedical Research (CBMR) , University of Algarve , Campus of Gambelas, Building 8, room 2.22 , 8005-139 Faro , Portugal
- Regenerative Medicine Program , Department of Biomedical Sciences and Medicine , University of Algarve , Campus de Gambelas , 8005-139 Faro , Portugal .
| | - James B Lorens
- Department of Biomedicine , Centre for Cancer Biomarkers , University of Bergen , Jonas Lies Vei 91 , 5009 Bergen , Norway
| |
Collapse
|
18
|
Cautain B, Castillo F, Musso L, Ferreira BI, de Pedro N, Rodriguez Quesada L, Machado S, Vicente F, Dallavalle S, Link W. Discovery of a Novel, Isothiazolonaphthoquinone-Based Small Molecule Activator of FOXO Nuclear-Cytoplasmic Shuttling. PLoS One 2016; 11:e0167491. [PMID: 27936162 PMCID: PMC5147912 DOI: 10.1371/journal.pone.0167491] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2016] [Accepted: 10/26/2016] [Indexed: 01/01/2023] Open
Abstract
FOXO factors are tumour suppressor proteins commonly inactivated in human tumours by posttranslational modifications. Furthermore, genetic variation within the FOXO3a gene is consistently associated with human longevity. Therefore, the pharmacological activation of FOXO proteins is considered as an attractive therapeutic approach to treat cancer and age-related diseases. In order to identify agents capable of activating FOXOs, we tested a collection of small chemical compounds using image-based high content screening technology. Here, we report the discovery of LOM612 (compound 1a), a newly synthesized isothiazolonaphthoquinone as a potent FOXO relocator. Compound 1a induces nuclear translocation of a FOXO3a reporter protein as well as endogenous FOXO3a and FOXO1 in U2OS cells in a dose-dependent manner. This activity does not affect the subcellular localization of other cellular proteins including NFkB or inhibit CRM1-mediated nuclear export. Furthermore, compound 1a shows a potent antiproliferative effect in human cancer cell lines.
Collapse
Affiliation(s)
- Bastien Cautain
- Fundacion MEDINA, Parque Tecnológico Ciencias de la Salud, Granada, Spain
| | - Francisco Castillo
- Fundacion MEDINA, Parque Tecnológico Ciencias de la Salud, Granada, Spain
| | - Loana Musso
- DeFENS Department of Food, Environmental and Nutritional Sciences, Università di Milano, Italy
| | - Bibiana I. Ferreira
- Centre for Biomedical Research (CBMR), Gambelas Campus, Faro, Portugal
- Regenerative Medicine Program, Department of Biomedical Sciences and Medicine, University of Algarve, Campus de Gambelas, Faro, Portugal
| | - Nuria de Pedro
- Fundacion MEDINA, Parque Tecnológico Ciencias de la Salud, Granada, Spain
| | | | - Susana Machado
- Centre for Biomedical Research (CBMR), Gambelas Campus, Faro, Portugal
| | - Francisca Vicente
- Fundacion MEDINA, Parque Tecnológico Ciencias de la Salud, Granada, Spain
| | - Sabrina Dallavalle
- DeFENS Department of Food, Environmental and Nutritional Sciences, Università di Milano, Italy
| | - Wolfgang Link
- Centre for Biomedical Research (CBMR), Gambelas Campus, Faro, Portugal
- Regenerative Medicine Program, Department of Biomedical Sciences and Medicine, University of Algarve, Campus de Gambelas, Faro, Portugal
- * E-mail:
| |
Collapse
|
19
|
Carracedo A, Salido M, Corominas JM, Rojo F, Ferreira BI, Suela J, Tusquets I, Corzo C, Segura M, Espinet B, Cigudosa JC, Arumi M, Albanell J, Serrano S, Solé F. Are ER+PR+ and ER+PR- breast tumors genetically different? A CGH array study. Cancer Genet 2012; 205:138-46. [PMID: 22559974 DOI: 10.1016/j.cancergen.2012.01.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2011] [Revised: 12/03/2011] [Accepted: 01/03/2012] [Indexed: 11/29/2022]
Abstract
The estrogen receptor (ER) is a well-known predictor of breast cancer response to endocrine therapy. ER+ progesterone receptor (PR)- breast tumors have a poorer response to endocrine therapy and a more aggressive phenotype than ER+PR+ tumors. A comparative genomic hybridization array technique was used to examine 25 ER+PR+ and 23 ER+PR- tumors. Tissue microarrays composed of 50 ER+PR+ and 50 ER+PR- tumors were developed to validate the comparative genomic hybridization array results. The genes of interest were analyzed by fluorescence in situ hybridization. The ER+PR- group had a slightly different genomic profile when compared with ER+PR+ tumors. Chromosomes 17 and 20 contained the most overlapping gains, and chromosomes 3, 8, 9, 14, 17, 21, and 22 contained the most overlapping losses when compared with the ER+PR+ group. The gained regions, 17q23.2-q23.3 and 20q13.12, and the lost regions, 3p21.32-p12.3, 9pter-p13.2, 17pter-p12, and 21pter-q21.1, occurred at different alteration frequencies and were statistically significant in the ER+PR- tumors compared with the ER+PR+ tumors. ER+PR- breast tumors have a different genomic profile compared with ER+PR+ tumors. Differentially lost regions in the ER+PR- group included genes with tumor suppressor functions and genes involved in apoptosis, mitosis, angiogenesis, and cell spreading. Differentially gained regions included genes such as MAP3K3, RPS6KB1, and ZNF217. Amplification of these genes could contribute to resistance to apoptosis, increased activation of the PI3K/Akt/mTOR pathway, and the loss of PR in at least some ER+PR- tumors.
Collapse
Affiliation(s)
- Alma Carracedo
- Pathology Service, Molecular Cytogenetics Laboratory, Hospital del Mar, IMIM, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Rio-Machín A, Menezes J, Maiques-Diaz A, Agirre X, Ferreira BI, Acquadro F, Rodriguez-Perales S, Juaristi KA, Alvarez S, Cigudosa JC. Abrogation of RUNX1 gene expression in de novo myelodysplastic syndrome with t(4;21)(q21;q22). Haematologica 2011; 97:534-7. [PMID: 22102704 DOI: 10.3324/haematol.2011.050567] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The disruption of RUNX1 function is one of the main mechanisms of disease observed in hematopoietic malignancies and the description of novel genetic events that lead to a RUNX1 loss of function has been accelerated with the development of genomic technologies. Here we describe the molecular characterization of a new t(4;21)(q21;q22) in a de novo myelodysplastic syndrome that resulted in the deletion of the RUNX1 gene. We demonstrated by quantitative real-time RT-PCR an almost complete depletion of the expression of the RUNX1 gene in our t(4;21) case compared with CD34(+) cells that was independent of mutation or DNA methylation. More importantly, we explored and confirmed the possibility that this abrogation also prevented transactivation of RUNX1 target genes, perhaps confirming the genetic origin of the thrombocytopenia and the myelodysplastic features observed in our patient, and certainly mimicking what has been observed in the presence of the RUNX1/ETO fusion protein.
Collapse
Affiliation(s)
- Ana Rio-Machín
- Molecular Cytogenetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre - CNIO, Melchor Fernández Almagro, 3, 28029, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Sánchez-Schmidt JM, Salgado R, Servitje O, Gallardo F, Ortiz-Romero PL, Karpova MB, Zipser MC, García-Muret MP, Estrach T, Rodríguez-Pinilla SM, Climent F, Suela J, Ferreira BI, Cigudosa JC, Salido M, Barranco C, Serrano S, Dummer R, Solé F, Pujol RM, Espinet B. Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide arrayCGH approach. J Invest Dermatol 2010; 131:269-71. [PMID: 20844552 DOI: 10.1038/jid.2010.271] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
22
|
Di Lisio L, Gómez-López G, Sánchez-Beato M, Gómez-Abad C, Rodríguez ME, Villuendas R, Ferreira BI, Carro A, Rico D, Mollejo M, Martínez MA, Menárguez J, Díaz-Alderete A, Gil J, Cigudosa JC, Pisano DG, Piris MA, Martínez N. Mantle cell lymphoma: transcriptional regulation by microRNAs. Leukemia 2010; 24:1335-42. [PMID: 20485376 DOI: 10.1038/leu.2010.91] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Mantle cell lymphoma (MCL) pathogenesis is still partially unexplained. We investigate the importance of microRNA (miRNA) expression as an additional feature that influences MCL pathway deregulation and may be useful for predicting patient outcome. Twenty-three MCL samples, eight cell lines and appropriate controls were screened for their miRNAs and gene expression profiles and DNA copy-number changes. MCL patients exhibit a characteristic signature that includes 117 miRNA (false discovery rate <0.05). Combined analysis of miRNAs and the gene expression profile, paired with bioinformatics target prediction (miRBase and TargetScan), revealed a series of genes and pathways potentially targeted by a small number of miRNAs, including essential pathways for lymphoma survival such as CD40, mitogen-activated protein kinase and NF-kappaB. Functional validation in MCL cell lines demonstrated NF-kappaB subunit nuclear translocation to be regulated by the expression of miR-26a. The expression of 12 selected miRNAs was studied by quantitative PCR in an additional series of 54 MCL cases. Univariate analysis identified a single miRNA, miR-20b, whose lack of expression distinguished cases with a survival probability of 56% at 60 months. In summary, using a novel bioinformatics approach, this study identified miRNA changes that contribute to MCL pathogenesis and markers of potential utility in MCL diagnosis and clinical prognostication.
Collapse
Affiliation(s)
- L Di Lisio
- Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Salgado R, Servitje O, Gallardo F, Vermeer MH, Ortiz-Romero PL, Karpova MB, Zipser MC, Muniesa C, García-Muret MP, Estrach T, Salido M, Sánchez-Schmidt J, Herrera M, Romagosa V, Suela J, Ferreira BI, Cigudosa JC, Barranco C, Serrano S, Dummer R, Tensen CP, Solé F, Pujol RM, Espinet B. Oligonucleotide Array-CGH Identifies Genomic Subgroups and Prognostic Markers for Tumor Stage Mycosis Fungoides. J Invest Dermatol 2010; 130:1126-35. [DOI: 10.1038/jid.2009.306] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
24
|
Ferreira BI, García JF, Suela J, Mollejo M, Camacho FI, Carro A, Montes S, Piris MA, Cigudosa JC. Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. Haematologica 2008; 93:670-9. [PMID: 18367492 DOI: 10.3324/haematol.12221] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Low-grade B-cell lymphomas are a very heterogeneous group of tumors, whose differential diagnosis is frequently compromised by the lack of specific cytogenetic or molecular features. Our objective was to search for genomic features that allow a better molecular identification of the different types of lymphoma studied. DESIGN AND METHODS We selected a panel of 87 low-grade B-cell lymphoma tumor samples that were unambiguously diagnosed (clinically and cytogenetically) as: follicular, splenic marginal zone, nodal marginal zone, lymphoplasmacytic, mantle cell, extranodal marginal zone MALT-type lymphoma or B-cell chronic lymphocytic leukemia. All samples were subjected to the same high-resolution genomic DNA analysis (array-based comparative genomic hybridization): a whole genome platform that contained 44000 probes distributed across the genome. Genomic imbalances were recorded, compiled and analyzed. RESULTS Eighty percent of analyzed cases showed genomic imbalances (deletions and gain/amplifications) but the frequency of these imbalances ranged from 100% in mantle cell lymphomas to 33% in MALT lymphomas. A total of 95 new genomic imbalances affecting all lymphoma subtypes, were defined. We evaluated the extension of the genomic instability, detecting distinct patterns of genomic instability within subtypes. Specific pathways, such as nuclear factor kB (gains of REL and BCL11A, and losses of COMMD3, BIRC1, IKK1 and NFKB2), Polycomb group proteins (gain of BMI1 and deletion of PCGF6), DNA repair checkpoint pathways (deletion of 16q24 involving CDT1), or miRNA with a role in B-cell lymphoma pathogenesis (MIRN15A, MIRN16-1), were targeted by this genomic instability. CONCLUSIONS Although all subtypes of lymphomas showed gains and losses of DNA, the analysis of their genomic profiles indicated that there are specific aberrations in almost every subtype as well as frequent aberrations that are common to a large number of lymphoma types. These common aberrations target genes that are important in B-cell lymphomagenesis.
Collapse
Affiliation(s)
- Bibiana I Ferreira
- Molecular Cytogenetics Group, Centro Nacional Investigaciones Oncologicas (CNIO), Melchor Fernandez Almagro, 3, 28029 Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Ferreira BI, Alonso J, Carrillo J, Acquadro F, Largo C, Suela J, Teixeira MR, Cerveira N, Molares A, Goméz-López G, Pestaña A, Sastre A, Garcia-Miguel P, Cigudosa JC. Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. Oncogene 2007; 27:2084-90. [PMID: 17952124 DOI: 10.1038/sj.onc.1210845] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Ewing's sarcoma (ES) is characterized by specific chromosome translocations, the most common being t(11;22)(q24;q12). Additionally, other type of genetic abnormalities may occur and be relevant for explaining the variable tumour biology and clinical outcome. We have carried out a high-resolution array CGH and expression profiling on 25 ES tumour samples to characterize the DNA copy number aberrations (CNA) occurring in these tumours and determine their association with gene-expression profiles and clinical outcome. CNA were observed in 84% of the cases. We observed a median number of three aberrations per case. Besides numerical chromosome changes, smaller aberrations were found and defined at chromosomes 5p, 7q and 9p. All CNA were compiled to define the smallest overlapping regions of imbalance (SORI). A total of 35 SORI were delimited. Bioinformatics analyses were conducted to identify subgroups according to the pattern of genomic instability. Unsupervised and supervised clustering analysis (using SORI as variables) segregated the tumours in two distinct groups: one genomically stable (< or =3 CNA) and other genomically unstable (>3 CNA). The genomic unstable group showed a statistically significant shorter overall survival and was more refractory to chemotherapy. Expression profile analysis revealed significant differences between both groups. Genes related with chromosome segregation, DNA repair pathways and cell-cycle control were upregulated in the genomically unstable group. This report elucidates, for the first time, data about genomic instability in ES, based on CNA and expression profiling, and shows that a genomically unstable group of Ewing's tumours is correlated with a significant poor prognosis.
Collapse
Affiliation(s)
- B I Ferreira
- Molecular Cytogenetics Group, Centro Nacional de Investigaciones Oncológicas (CNIO), and CIBER on Rare Diseases (CIBERER), Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Suela J, Alvarez S, Cifuentes F, Largo C, Ferreira BI, Blesa D, Ardanaz M, García R, Marquez JA, Odero MD, Calasanz MJ, Cigudosa JC. DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia 2007; 21:1224-31. [PMID: 17377590 DOI: 10.1038/sj.leu.2404653] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We have carried out a high-resolution whole genome DNA profiling analysis on 100 bone marrow samples from a consecutive series of de novo acute myeloid leukemia (AML) cases. After discarding copy number changes that are known to be genetic polymorphisms, we found that genomic aberrations (GA) in the form of gains or losses of genetic material were present in 74% of the samples, with a median of 2 GA per case (range 0-35). In addition to the cytogenetically detected aberration, GA were present in cases from all cytogenetic prognostic groups: 79% in the favorable group, 60% in the intermediate group (including 59% of cases with normal karyotype) and 83% in the adverse group. Five aberrant deleted regions were recurrently associated with cases with a highly aberrant genome (e.g., a 1.5 Mb deletion at 17q11.2 and a 750 kb deletion at 5q31.1). Different degrees of genomic instability showed a statistically significant impact on survival curves, even within the normal karyotype cases. This association was independent of other clinical and genetic parameters. Our study provides, for the first time, a detailed picture of the nature and frequency of DNA copy number aberrations in de novo AML.
Collapse
Affiliation(s)
- J Suela
- Molecular Cytogenetics Group, Centro Nacional Investigaciones Oncologicas, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|